礼来(LLY.US)阿尔茨海默病药物Kisunla获欧盟支持获批用于特定患者群体

智通财经2025-07-25

智通财经APP获悉，礼来公司(LLY.US)的阿尔茨海默病药物Kisunla获得欧盟监管机构支持，获批用于特定患者群体。这一进展或为其成为欧洲地区第二款延缓老年痴呆最常见病因的药物铺平道路。欧洲药品管理局(EMA)的药物咨询委员会建议，批准Kisunla用于携带特定基因变异拷贝数为0或1的患者。该基因变异可能增加患“淀粉样蛋白相关成像异常(ARIA)”的风险——这是一种可能致命的脑部肿胀疾病。而在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2554376748?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-25 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554376748","market":"hk","top_or_hot":-1,"title":"礼来(LLY.US)阿尔茨海默病药物Kisunla获欧盟支持 获批用于特定患者群体","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，礼来公司(LLY.US)的阿尔茨海默病药物Kisunla获得欧盟监管机构支持，获批用于特定患者群体。这一进展或为其成为欧洲地区第二款延缓老年痴呆最常见病因的药物铺平道路。欧洲药品管理局(EMA)的药物咨询委员会建议，批准Kisunla用于携带特定基因变异拷贝数为0或1的患者。该基因变异可能增加患“淀粉样蛋白相关成像异常(ARIA)”的风险——这是一种可能致命的脑部肿胀疾病。而在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1322172.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来(LLY.US)阿尔茨海默病药物Kisunla获欧盟支持 获批用于特定患者群体</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来(LLY.US)阿尔茨海默病药物Kisunla获欧盟支持 获批用于特定患者群体\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-25 20:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1322172.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，礼来公司(LLY.US)的阿尔茨海默病药物Kisunla获得欧盟监管机构支持，获批用于特定患者群体。这一进展或为其成为欧洲地区第二款延缓老年痴呆最常见病因的药物铺平道路。欧洲药品管理局(EMA)的药物咨询委员会建议，批准Kisunla用于携带特定基因变异拷贝数为0或1的患者。该基因变异可能增加患“淀粉样蛋白相关成像异常(ARIA)”的风险——这是一种可能致命的脑部肿胀疾病。而在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1322172.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999018857.SGD","symbol_name":"United Global Quality Growth Fd Cl Acc SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1322172.html","article_id":"2554376748","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554376748","pubTimestamp":1753446854,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，礼来公司的阿尔茨海默病药物Kisunla获得欧盟监管机构支持，获批用于特定患者群体。欧洲药品管理局的药物咨询委员会建议，批准Kisunla用于携带特定基因变异拷贝数为0或1的患者。目前，欧洲委员会仍需对Kisunla的获批进行最终确认，之后该药物方可在欧盟范围内使用。这一举措将礼来与卫材在阿尔茨海默病药物市场的竞争推向新阶段。此前，礼来已在美国、日本和英国获得Kisunla的上市批准。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4581":"高盛持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2063271972.USD":"富兰克林创新领域基金","LU0385154629.USD":"贝莱德营养科学基金A2","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LLY":"礼来","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC"},"translate_title":"Eli Lilly (LLY.US) Alzheimer's disease drug Kisunla receives EU support and is approved for specific patient groups","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FESXmain":1,"LLY":1,"FSXEmain":1},"content_text":"智通财经APP获悉，礼来公司(LLY.US)的阿尔茨海默病药物Kisunla获得欧盟监管机构支持，获批用于特定患者群体。这一进展或为其成为欧洲地区第二款延缓老年痴呆最常见病因的药物铺平道路。欧洲药品管理局(EMA)的药物咨询委员会建议，批准Kisunla用于携带特定基因变异拷贝数为0或1的患者。该基因变异可能增加患“淀粉样蛋白相关成像异常(ARIA)”的风险——这是一种可能致命的脑部肿胀疾病。而在美国，这款药物的获批适用人群范围更广。欧盟此前已批准卫材(Eisai)与渤健(Biogen)联合研发的同类药物Leqembi，但其使用同样限于脑部肿胀风险较低的患者。周五盘前交易中，礼来股价小幅上涨0.5%。截至周四收盘，该股过去12个月累计下跌约2%。欧洲药品管理局表示，Kisunla能够减缓阿尔茨海默病相关的认知和功能障碍进展，最常见的副作用为ARIA和头痛。目前，欧洲委员会仍需对Kisunla的获批进行最终确认，之后该药物方可在欧盟范围内使用。此次积极意见推翻了此前的负面结论，与Leqembi在欧盟获批时的情况如出一辙。礼来通过提交新的分析数据、收集患者及医护人员反馈，以及提出新的给药方案和降低ARIA风险的额外措施，最终实现了这一逆转。这一举措将礼来与卫材在阿尔茨海默病药物市场的竞争推向新阶段。该领域长期受挫折、安全隐患及市场接受度低等问题困扰，彭博情报已因此将2030年该市场规模预期减半至60亿美元。据彭博汇编的预测，届时Kisunla单药销售额或达约20亿美元。两款药物均通过输液方式清除脑部有毒的淀粉样蛋白，虽能适度延缓病情，但仅获批用于早期阿尔茨海默病患者——这一群体在总患者中占比不高。此外，两款药物均存在副作用，包括潜在的脑部肿胀和出血风险。此前，礼来已在美国、日本和英国获得Kisunla的上市批准。相较于每两周给药一次的Leqembi，Kisunla每月输液一次的给药频率可能更具便利性优势。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554376748","isCrawlerRequest":true}

礼来(LLY.US)阿尔茨海默病药物Kisunla获欧盟支持 获批用于特定患者群体

精彩评论

礼来(LLY.US)阿尔茨海默病药物Kisunla获欧盟支持获批用于特定患者群体